EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH

View source ↗

Summary

The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Juvenile Rheumatoid
• Arthritis Psoriatic
• Arthritis Rheumatoid
• Hidradenitis Suppurativa
• Psoriasis
• Spondylitis Ankylosing
• Uveitis

Drugs mentioned

• Halimatoz (adalimumab)

Snippet

Status: Withdrawn. Therapeutic area: Hidradenitis Suppurativa;Psoriasis;Arthritis, Juvenile Rheumatoid;Uveitis;Arthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic. MAH: Sandoz GmbH. Decision date: 18/12/2020